Lipoprotein(a) has been studied as a risk factor for coronary heart disease, but whether a causal relationship exists has been unclear. A study by Kamstrup and colleagues examining genetically mediated increases in lipoprotein(a) concentration now provides evidence that it could indeed represent a causal coronary risk factor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anuurad, E., Boffa, M. B., Koschinsky, M. L. & Berglund, L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26, 751–772 (2006).
Berg, K. A new serum type system in man—the Lp system. Acta Pathol. Microbiol. Scand. 59, 369–382 (1963).
Kamstrup, P. R., Tybjaerg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–2339 (2009).
Barnathan, E. S. Has lipoprotein 'little' (a) shrunk? JAMA 270, 2224–2225 (1993).
Marcovina, S. M., Koschinsky, M. L., Albers, J. J. & Skarlatos, S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin. Chem. 49, 1785–1796 (2003).
Bennet, A. et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168, 598–608 (2008).
The Emerging Risk Factors Collaboration. Lipoprotein(a) and risk of coronary heart disease and ischemic stroke. JAMA 302, 412–423 (2009).
Keavney, B. et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int. J. Epidemiol. 35, 935–943 (2006).
Tregouet, D. A. et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283–285 (2009).
Tsimikas, S., Tsironis, L. D. & Tselepis, A, D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094–2099 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. Danesh has received grants from the British Heart Foundation, BUPA Foundation, European Union, Evelyn Trust, GlaxoSmithKline, Medical Research Council, Merck Sharp and Dohme, Novartis and the Wellcome Trust, and donations of assay kits from diaDexus and Roche.
S. Erqou has received consultancy payments from GlaxoSmithKline for work on meta-analyses.
Rights and permissions
About this article
Cite this article
Danesh, J., Erqou, S. Lipoprotein(a) and coronary disease—moving closer to causality. Nat Rev Cardiol 6, 565–567 (2009). https://doi.org/10.1038/nrcardio.2009.138
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.138
This article is cited by
-
Amperometric magnetoimmunoassay for the determination of lipoprotein(a)
Microchimica Acta (2015)